MustGrow Biologics Logo
CA62822A1030
A2PNS7
MGRO.V

MustGrow Biologics

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • MustGrow Biologics returns to profit in Q2 2026 thanks to license income

    MustGrow reported a net income of CAD 300,000 for Q2/2026 versus a loss of CAD 1.1m a year earlier, supported by CAD 1.4m in license revenue. Core product TerraSante generated only CAD 75,000 in revenue and a negative gross profit of CAD 17,000 as production issues and expensive air freight weighed on margins. Management plans to switch to sea freight, expects mid‑term gross margins of around 25–30% and is building inventories for 2027; cash stood at CAD 4.4m and working capital at CAD 5.2m. » More on de.investing.com


  • MustGrow advances commercialization with TerraSante registrations, Bayer testing agreement and C$3.74m financing

    MustGrow is expanding commercial rollout of its mustard-derived product TerraSante with new U.S. registrations including Texas, broadening its market access. The company has an exclusive agreement with Bayer for testing and potential rights to several applications across EMEA and APAC, with Bayer funding development and regulatory work. MustGrow completed a C$3.74 million private placement to fund inventory and working capital and received a BUY initiation from GBC with upside revenue forecasts, while commercial adoption and regulatory progress remain key execution risks. » More on finance.yahoo.com


  • MustGrow Biologics posts surge in 2025 revenue as TerraSante US sales accelerate

    MustGrow Biologics reported revenue of $8.3m for 2025, up from $0.4m in 2024, driven by strong US sales of its TerraSante biofertility product. US TerraSante sales rose to $0.6m, a 377% increase, while gross margin was 20%. Operating expenses increased to $7.7m, widening the net loss to $7.3m as the company scaled commercial activity and third-party manufacturing. Management expects continued TerraSante sales growth and margin improvement in 2026 as production shifts to continuous contract manufacturing and US tariffs become more favorable. » More on finance.yahoo.com


  • MustGrow Biologics boosts gross margin in Q3 despite net loss

    MustGrow Biologics reported an improved gross margin of 22% for Q3 2025 alongside a net loss of $2.4 million. Revenue of $180,560 fell well short of expectations of $5.2 million, while EPS of -0.04 matched forecasts. The stock rose 6.78% after the results. The company is targeting cash-flow break-even in 2026 and plans expansion in Brazil, Mexico and the Netherlands, but sees risks from inventory shortages, tariffs and regulatory hurdles. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2010, MustGrow Biologics has already paid €0.78 in dividends. The last payout was in August 2010.

Financials

In the last quarter, MustGrow Biologics had revenue of €887.33K and net profit of €175.65K
(EUR) June 2026
YoY
Revenue 887.33K 50.06%
Gross profit 840.14K 126.55%
Net profit 175.65K 125.87%
EBITDA 265.21K 141.57%

Fundamentals

Metric Value
Market capitalization
€15.97M
Number of shares
70.4M
52-week high/low
€0.61 - €0.20
Dividends No
Beta
0.33
P/E ratio
-3.81
PEG ratio
-0.55
P/B ratio
4.68
P/S ratio
8.16

Company profile

MustGrow Biologics Corp., an agricultural biotech company, focuses om development and commercialization of natural biopesticide, biofumigants, and bioherbicides derived from mustard seed. It provides preplant soil biofumigation, a technology to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and other crops. The company is also developing bioherbicide to treat unwanted plant growth for use in organic agriculture, home, and garden markets, as well as agriculture markets; and postharvest food preservation, an application in sprout, disease, and pathogen treatment for storage and food preservation markets. In addition, it focuses on providing CannaPM, an active ingredient to treat fungal soil diseases, as well as foliar diseases. The company was formerly known as Duport Capital Ltd. and changed its name to MustGrow Biologics Corp. in March 2018. MustGrow Biologics Corp. was incorporated in 2014 and is headquartered in Saskatoon, Canada.

Name
MustGrow Biologics
CEO
Corey J. Giasson
Headquarters Saskatoon, sk
Canada
Website
Sector
Health Care
Industry
Biotechnology
IPO
11/21/2019
Employees 10

Ticker symbols

Exchange Symbol
Tsxv
MGRO.V
Pnk
MGROF
Frankfurt
0C0.F
Düsseldorf
0C0.DU
🍪

Parqet  uses cookies. Learn more